SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost
Само за регистроване кориснике
2024
Аутори
Lijeskić, OliveraBauman, Neda
Marković, Miloš
Srbljanović, Jelena
Bobić, Branko
Zlatković, Đorđe
Štajner, Tijana
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
The aim of this study was to evaluate immunogenicity and longevity of the humoral immune response within six months after the homologous (BNT162b2/BNT162b2) or heterologous (BBIBP-CorV/BNT162b2) third dose, and to assess breakthrough infections among vaccinees during the Omicron wave in Serbia. Serum samples were analyzed at four timepoints: five months after the primary series; three weeks, three months, and six months after the boost. IgG antibodies against the receptor-binding domain of the spike protein were detected using enzyme-linked fluorescence assay. Both homologous (n = 55) and heterologous group (n = 36) showed a highly significant increase in antibody concentrations (p < 0.001) three weeks after the boost. A moderate inverse correlation between the age of recipients and the antibody levels at three weeks post-boost was observed in the homologous group (p = 0.02, r = −0.37), while the same correlation was not significant for heterologous group (p = 0.55, r = −0.15). Heterol...ogous group had significantly higher antibody concentrations than homologous group at three weeks (Median 851.4(IQR 766.6–894.1); 784.3(676.9–847.4); p = 0.03) and three months post-boost (766.6(534.8–798.9); 496.8(361.6–664.0); p < 0.001). However, a significant decline in antibody response over time was noted for both strategies. The overall incidence of breakthrough cases was estimated at 36.36% (20/55) for homologous, and 16.67% (6/36) for heterologous group, but none of them required hospitalization. Although observed incidence in the homologous group was more than double when compared to the heterologous group, this difference was not statistically significant, most likely due to the small sample size. In conclusion, waning immunity after inactivated vaccine can be recovered by BNT162b2 heterologous boost regardless of the age of recipients, and both boost strategies induced potent humoral immune response and protection against severe COVID-19 during the Omicron wave. However, as the observed incidence of breakthrough infections was higher in the homologous group, although non-significant, this finding could indicate an advantage of heterologous approach.
Кључне речи:
Homologous boost / Heterologous boost / SARS-CoV-2 vaccines / BBIBP-CorV / OmicronИзвор:
Vaccine, 2024, 42, 7, 1665-1672Издавач:
- Elsevier
Финансирање / пројекти:
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200015 (Универзитет у Београду, Институт за медицинска истраживања) (RS-MESTD-inst-2020-200015)
Институција/група
Institut za medicinska istraživanjaTY - JOUR AU - Lijeskić, Olivera AU - Bauman, Neda AU - Marković, Miloš AU - Srbljanović, Jelena AU - Bobić, Branko AU - Zlatković, Đorđe AU - Štajner, Tijana PY - 2024 UR - http://rimi.imi.bg.ac.rs/handle/123456789/1462 AB - The aim of this study was to evaluate immunogenicity and longevity of the humoral immune response within six months after the homologous (BNT162b2/BNT162b2) or heterologous (BBIBP-CorV/BNT162b2) third dose, and to assess breakthrough infections among vaccinees during the Omicron wave in Serbia. Serum samples were analyzed at four timepoints: five months after the primary series; three weeks, three months, and six months after the boost. IgG antibodies against the receptor-binding domain of the spike protein were detected using enzyme-linked fluorescence assay. Both homologous (n = 55) and heterologous group (n = 36) showed a highly significant increase in antibody concentrations (p < 0.001) three weeks after the boost. A moderate inverse correlation between the age of recipients and the antibody levels at three weeks post-boost was observed in the homologous group (p = 0.02, r = −0.37), while the same correlation was not significant for heterologous group (p = 0.55, r = −0.15). Heterologous group had significantly higher antibody concentrations than homologous group at three weeks (Median 851.4(IQR 766.6–894.1); 784.3(676.9–847.4); p = 0.03) and three months post-boost (766.6(534.8–798.9); 496.8(361.6–664.0); p < 0.001). However, a significant decline in antibody response over time was noted for both strategies. The overall incidence of breakthrough cases was estimated at 36.36% (20/55) for homologous, and 16.67% (6/36) for heterologous group, but none of them required hospitalization. Although observed incidence in the homologous group was more than double when compared to the heterologous group, this difference was not statistically significant, most likely due to the small sample size. In conclusion, waning immunity after inactivated vaccine can be recovered by BNT162b2 heterologous boost regardless of the age of recipients, and both boost strategies induced potent humoral immune response and protection against severe COVID-19 during the Omicron wave. However, as the observed incidence of breakthrough infections was higher in the homologous group, although non-significant, this finding could indicate an advantage of heterologous approach. PB - Elsevier T2 - Vaccine T2 - Vaccine T1 - SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost EP - 1672 IS - 7 SP - 1665 VL - 42 DO - 10.1016/j.vaccine.2024.01.085 ER -
@article{ author = "Lijeskić, Olivera and Bauman, Neda and Marković, Miloš and Srbljanović, Jelena and Bobić, Branko and Zlatković, Đorđe and Štajner, Tijana", year = "2024", abstract = "The aim of this study was to evaluate immunogenicity and longevity of the humoral immune response within six months after the homologous (BNT162b2/BNT162b2) or heterologous (BBIBP-CorV/BNT162b2) third dose, and to assess breakthrough infections among vaccinees during the Omicron wave in Serbia. Serum samples were analyzed at four timepoints: five months after the primary series; three weeks, three months, and six months after the boost. IgG antibodies against the receptor-binding domain of the spike protein were detected using enzyme-linked fluorescence assay. Both homologous (n = 55) and heterologous group (n = 36) showed a highly significant increase in antibody concentrations (p < 0.001) three weeks after the boost. A moderate inverse correlation between the age of recipients and the antibody levels at three weeks post-boost was observed in the homologous group (p = 0.02, r = −0.37), while the same correlation was not significant for heterologous group (p = 0.55, r = −0.15). Heterologous group had significantly higher antibody concentrations than homologous group at three weeks (Median 851.4(IQR 766.6–894.1); 784.3(676.9–847.4); p = 0.03) and three months post-boost (766.6(534.8–798.9); 496.8(361.6–664.0); p < 0.001). However, a significant decline in antibody response over time was noted for both strategies. The overall incidence of breakthrough cases was estimated at 36.36% (20/55) for homologous, and 16.67% (6/36) for heterologous group, but none of them required hospitalization. Although observed incidence in the homologous group was more than double when compared to the heterologous group, this difference was not statistically significant, most likely due to the small sample size. In conclusion, waning immunity after inactivated vaccine can be recovered by BNT162b2 heterologous boost regardless of the age of recipients, and both boost strategies induced potent humoral immune response and protection against severe COVID-19 during the Omicron wave. However, as the observed incidence of breakthrough infections was higher in the homologous group, although non-significant, this finding could indicate an advantage of heterologous approach.", publisher = "Elsevier", journal = "Vaccine, Vaccine", title = "SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost", pages = "1672-1665", number = "7", volume = "42", doi = "10.1016/j.vaccine.2024.01.085" }
Lijeskić, O., Bauman, N., Marković, M., Srbljanović, J., Bobić, B., Zlatković, Đ.,& Štajner, T.. (2024). SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost. in Vaccine Elsevier., 42(7), 1665-1672. https://doi.org/10.1016/j.vaccine.2024.01.085
Lijeskić O, Bauman N, Marković M, Srbljanović J, Bobić B, Zlatković Đ, Štajner T. SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost. in Vaccine. 2024;42(7):1665-1672. doi:10.1016/j.vaccine.2024.01.085 .
Lijeskić, Olivera, Bauman, Neda, Marković, Miloš, Srbljanović, Jelena, Bobić, Branko, Zlatković, Đorđe, Štajner, Tijana, "SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost" in Vaccine, 42, no. 7 (2024):1665-1672, https://doi.org/10.1016/j.vaccine.2024.01.085 . .